Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 04/12/19
End: 11/11/21
Due: 11/11/22
Phase: N/A
Priority: Normal
Start: 12/16/24
End: 12/16/28
Due: 12/16/29
Phase: N/A
Priority: Normal
Start: 06/30/17
End: 01/30/23
Due: 01/30/24
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer（ALTER-L029） | NCT03743129 | Anhui Shi, MD | user2@example.com | None | 2019-04-12 | 2021-11-11 | 2022-11-11 | - | - | 2025-07-14 |
| Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001) | NCT06719336 | Anhui Shi, MD | user2@example.com | None | 2024-12-16 | 2028-12-16 | 2029-12-16 | - | - | 2025-07-14 |
| Twice-daily SIB Radiotherapy Versus Standard Radiotherapy for Patients With SCLC | NCT03214003 | Anhui Shi, MD | user2@example.com | None | 2017-06-30 | 2023-01-30 | 2024-01-30 | - | - | 2025-07-14 |